Abstract
Extraintestinal manifestations (EIM) in inflammatory bowel disease (IBD) occur frequently and may present themselves before or after IBD diagnosis. They most commonly affect the eyes, skin, and joints, but can also involve other organs such as the liver. Some EIM are associated with intestinal disease activity and ameliorate by treatment of the underlying IBD. This is seen in patients with peripheral Type 1 arthritis, oral aphthous ulcers, episcleritis, and erythema nodosum. Other EIM are intestinal disease activity-independent such as uveitis, and ankylosing spondylitis. Finally, some EIM (e.g. pyoderma gangrenosum and primary sclerosing cholangitis) may or may not be associated with the underlying IBD. Successful therapy of EIM is important for improving quality of life of IBD patients. TNF antibody therapy is an important treatment option for EIM in IBD patients whereas no such beneficial effect was reported for alpha 4 beta 7 integrin antibodies such as vedolizumab so far. This article reviews the therapeutic experience with TNF antibodies for the treatment of EIM in IBD patients.
Keywords: Arthritis, extraintestinal manifestations, inflammatory bowel disease, uveitis.
Current Drug Targets
Title:Biologics for Extraintestinal Manifestations of IBD
Volume: 15 Issue: 11
Author(s): Stephan R. Vavricka, Michael Scharl, Martin Gubler and Gerhard Rogler
Affiliation:
Keywords: Arthritis, extraintestinal manifestations, inflammatory bowel disease, uveitis.
Abstract: Extraintestinal manifestations (EIM) in inflammatory bowel disease (IBD) occur frequently and may present themselves before or after IBD diagnosis. They most commonly affect the eyes, skin, and joints, but can also involve other organs such as the liver. Some EIM are associated with intestinal disease activity and ameliorate by treatment of the underlying IBD. This is seen in patients with peripheral Type 1 arthritis, oral aphthous ulcers, episcleritis, and erythema nodosum. Other EIM are intestinal disease activity-independent such as uveitis, and ankylosing spondylitis. Finally, some EIM (e.g. pyoderma gangrenosum and primary sclerosing cholangitis) may or may not be associated with the underlying IBD. Successful therapy of EIM is important for improving quality of life of IBD patients. TNF antibody therapy is an important treatment option for EIM in IBD patients whereas no such beneficial effect was reported for alpha 4 beta 7 integrin antibodies such as vedolizumab so far. This article reviews the therapeutic experience with TNF antibodies for the treatment of EIM in IBD patients.
Export Options
About this article
Cite this article as:
Vavricka R. Stephan, Scharl Michael, Gubler Martin and Rogler Gerhard, Biologics for Extraintestinal Manifestations of IBD, Current Drug Targets 2014; 15 (11) . https://dx.doi.org/10.2174/1389450115666140908125453
DOI https://dx.doi.org/10.2174/1389450115666140908125453 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Efficacy, Safety and Immunogenicity of Biosimilars in Inflammatory Bowel Diseases: A Systematic Review
Current Medicinal Chemistry Endothelial Dysfunction and the Effects of TNF Inhibitors on the Endothelium in Psoriasis and Psoriatic Arthritis: A Systematic Review
Current Pharmaceutical Design Inflammatory Arthritis and Heart Disease
Current Pharmaceutical Design Immunomodulatory Activity of Garlic
Current Immunology Reviews (Discontinued) Antibiotics in the Treatment of Reactive Arthritis
Current Rheumatology Reviews Volume Measurement in the Diagnosis of Mounier Kuhn Syndrome and an Unknown Accompanying Pathology: Pulmonary Artery Enlargement
Current Medical Imaging Current and Future Pharmaceutical Therapy for Rheumatoid Arthritis
Current Pharmaceutical Design Potential Role of Bioactive Lipids in Rheumatoid Arthritis
Current Pharmaceutical Design The Rationale for Comparative Studies of Accelerated Atherosclerosis in Rheumatic Diseases
Current Vascular Pharmacology Bio-Activities and Syntheses Developments of Triptolides
Mini-Reviews in Organic Chemistry Correlations and Influence of TAP2 Genes Polymorphisms and Systemic Lupus Erythematosus Propensity
Current Rheumatology Reviews Targeting Inflammation in Primary Cardiovascular Prevention
Current Pharmaceutical Design Ocular Inflammatory Diseases: Molecular Pathogenesis and Immunotherapy
Current Molecular Medicine Therapies Targeting Innate Immunity for Fighting Inflammation in Atherosclerosis
Current Pharmaceutical Design Naproxen: An Update on Physicochemical, Analytical and Pharmacological Aspects
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Role of Alpha-1 Antitrypsin (AAT) in Ocular Allergy and Uveitis
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Optimization of Aceclofenac Solid Dispersion Using Box-Behnken Design: in-vitro and in-vivo Evaluation
Current Drug Delivery Safety of Systemic Biologic Agents in the Treatment of Non-malignant Skin Disorders
Current Drug Safety The Therapeutic use of the Zonulin Inhibitor AT-1001 (Larazotide) for a Variety of Acute and Chronic Inflammatory Diseases
Current Medicinal Chemistry Macrophages in Immunopathology of Atherosclerosis: A Target for Diagnostics and Therapy
Current Pharmaceutical Design